AMD

RGC replacement represents a more formidable challenge.

Geographic atrophy is now a major research target.

Former smokers were at higher risk of having to undergo surgery for TED in a recent study, but the risk was lower than that associated with current smoking.

A recent study aimed to set the record straight on the occurrence of retinal vein occlusions (RVOs) following messenger RNA COVID-19 vaccinations.

Dr David Almeida shares two cases of neovascular AMD from his practice, one treatment-naïve and one previously treated, and presents his findings after switching them to faricimab.

David Almeida, MD, MBA, PhD, reviews the objectives and design of the TRUCKEE study, and discusses the visual and anatomic outcomes after one and three injections of faricimab in neovascular AMD.

Findings from a recent study suggest that AO retinal imaging has the potential to become a sensitive marker for MS.

Weighing the pros and cons of anti-VEGF drugs and improved visualisation of abnormalities in ROP

The spherical equivalent was significantly more myopic in the eyes treated with laser in a recent study.

Novel treatment results in macular hole closure.

The various aspects of home monitoring for patients with age-related macular degeneration are discussed in this point/counterpoint by Prof. Rufino Silva, University of Coimbra / Coimbra Hospital and University Centre, Portugal, and Univ.-Prof. Dr. med. Robert P. Finger, PhD, Department of Ophthalmology, University of Bonn, Germany, during the 14th annual Congress on Controversies in Ophthalmology in Lisbon, Portugal.

Antonio Campos, MD, PhD, discusses his position on a discussion titled Durability Associated with Multi-target Therapies is Superior to anti-VEGF Mono-target Therapy in AMD with David Hutton, Executive Editor, Ophthalmology Times.®

Session moderators, speakers and audience members all will examine and analyse the most relevant and controversial issues within the field of ophthalmology.

A look at what’s in the therapeutic delivery pipeline for these disorders.

Further research is needed before dietary nitrate intake can be recommended as a therapy for age-related macular degeneration, according to the study authors.

In a presentation at the Angiogenesis, Exudation, and Degeneration 2023 conference, Justis Ehlers, MD, presented "Ellipsoid Zone Integrity in Dry AMD: An Imaging Biomarker for Progression Risk and Clinical Trial Endpoint.”

Rishi Singh, MD, presented data from the Phase 3 DERBY and OAKS clinical trials for geographic atrophy at the 2023 Angiogenesis, Exudation, and Degeneration conference.

Carl D. Regillo, MD, highlights the Talon Phase 3b results for brolucizumab vs aflibercept in a matched treat-and-extend superiority study for neovascular AMD at the virtual 2023 Angiogenesis conference.

In a presentation at the 2023 Angiogenesis, Exudation, and Degeneration program, Usha Chakravarthy, PhD, FRCOphth, CBE, presented data from the trial of lampalizumab, which is peeling back some of the mystery shrouding geographic atrophy.

In a presentation at Bascom Palmer’s 2023 Angiogenesis, Exudation, and Degeneration conference in Miami, Pedro Lylyk, MD, said ophthalmic artery angioplasty could prove to be a treatment option for patients diagnosed with age-related macular degeneration.

A study conducted by Gemmy Cheung, MBBS, FRCOphth and colleagues shows geographic atrophy (GA) lesion phenotypes, associated features, and growth rates differ between Asians and non-Asians.

An interdisciplinary team at Duke University has developed a proof-of-concept machine learning model capable of detecting symptomatic Alzheimer disease using multimodal retinal imaging data.

The most promising recent interventional trials for investigational therapies in dry age-related macular degeneration are highlighted by the authors.

The delivery of lipid nanoparticle-based mRNA to the retina is encouraging, according to researchers.

Three recipients will each receive up to $10,000 toward their research on a 1-year project that can go toward additional training in specialty equipment or research methodologies.

Ultra-widefield imaging may be a promising technology for assessing larger areas of the retinal vasculature to uncover retinal changes in Alzheimer’s disease, according to investigators.

Understanding vitreomacular interface diseases is key to treatment.

Members of the Ophthalmology Times Europe® Editorial Advisory Board were asked to predict developments in their ophthalmic specialties and interests for 2023. A focus is our ageing population, while efficiency and productivity are also on their minds. The board members agree that one of the major challenges in the year to come will be the large number of patients awaiting diagnosis and treatment, which is only going to increase with the rising average life expectancy worldwide.

An end-of-week review of what happened in ophthalmology from 29 October to 3 November 2022.

The AVONELLE-X long-term extension study will continue to evaluate the efficacy, durability and safety of faricimab in patients with neovascular AMD.